# A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT06907615** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 243 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** HLX43 DOSE 1 (2.0 mg/kg)
- **DRUG:** HLX43 DOSE 2 (2.5 mg/kg)

## Key facts

- **NCT ID:** NCT06907615
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2028-04-20
- **Final completion:** 2028-06-04
- **Target enrollment:** 243 (ESTIMATED)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907615, "A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06907615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*